ArriVent BioPharma, Inc. Investigation - AVBP

Company
ArriVent BioPharma, Inc. (NASDAQ: AVBP)

Learn more about the ArriVent BioPharma, Inc. Investigation

Required Field

Required Field

Required Field

  • $1 - $1,000
  • $1001 - $10,000
  • $10,001 - $25,000
  • $25,001 - $50,000
  • $50,001 - $100,000
  • $100,001 - $250,000
  • $250,001 - $500,000
  • $500,000+

There is no cost or obligation for you to submit.

The submission of this form does not create an attorney-client relationship.

Please Upload related files below

Add Transactions

Purchases

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Purchases

Sales

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Sales

Please input at least 1 transaction or press "skip for now" button below

Please fill in all the fields for your transaction or press "skip for now" button below

Alternatively, you may upload your transactions below or e-mail them to [email protected]

Upload Your Stock Tickers

Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.

Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.

Skip

ArriVent BioPharma, Inc. Investigation Details

ArriVent BioPharma, Inc. shareholders lost money on October 6, 2026, when the stock fell sharply after the Company announced that its global Phase 3 FURVENT trial of firmonertinib failed to meet its primary endpoint of progression-free survival by blinded independent central review in previously untreated patients with EGFR exon 20 insertion--mutated non-small-cell lung cancer. On this news, the Company's shares collapsed roughly 50%--63% during the session, reaching a 52-week low near $12.09. Previously, on November 10, 2025, the Company filed an exhibit to Form 8-K representing that "An interim analysis for this study has not been performed and there is no plan to perform such analysis given the expected timing of top-line data." Later, on May 11, 2026, the Company filed a Form 424B5 prospectus supporting an at-the-market offering of up to $250,000,000, which described the Company as actively conducting the pivotal Phase 3 trial and seeking to support firmonertinib. The investigation concerns whether ArriVent BioPharma, Inc. adequately disclosed the clinical trial's progress and the timing of any negative efficacy data ahead of the October 6, 2026 announcement.

Get Started